CN Patent

CN105593215B — 用于治疗癌症的作为idh2突变体抑制剂的2,4-或4,6-二氨基嘧啶化合物

Assigned to Agios Pharmaceuticals Inc · Expires 2019-01-15 · 7y expired

What this patent protects

提供了具有化学式(I)的化合物， 其中：环A和环B各自独立地是任选地被取代的5‑6元单环的芳基或杂芳基；X、Y和W中的一个是CH并且其他两个是N；并且Z是H或‑C(R1)(R2)(R3)。这些化合物是有用于治疗癌症的异柠檬酸脱氢酶2(IDH2)突变体抑制剂。

USPTO Abstract

提供了具有化学式(I)的化合物， 其中：环A和环B各自独立地是任选地被取代的5‑6元单环的芳基或杂芳基；X、Y和W中的一个是CH并且其他两个是N；并且Z是H或‑C(R1)(R2)(R3)。这些化合物是有用于治疗癌症的异柠檬酸脱氢酶2(IDH2)突变体抑制剂。

Drugs covered by this patent

Patent Metadata

Patent number
CN105593215B
Jurisdiction
CN
Classification
—
Expires
2019-01-15
Drug substance claim
No
Drug product claim
No
Assignee
Agios Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.